Equity Profile

ELVN

Enliven Therapeutics, Inc.

Health CarePharmaceuticals$3.6B

Aug12Wed

Pre-Earnings Brief

UpcomingQ2-2026After Close5:00 PM EDT

Company Snapshot

Enliven Therapeutics, Inc. is a pharmaceutical company focused on developing innovative therapies for various health conditions....

Key Metrics to Watch

Earnings Per Share (EPS)

EPS is a key indicator of profitability and will help investors gauge the company's financial health this quarter.

N/A

Revenue Growth

Understanding revenue trends is essential for assessing the company's market performance and potential for future growth.

N/A

Wall Street expectations, options signals, track record, and call prep available with Pro.

ELVN Q2-2026 Earnings Preview

Context

Company Snapshot

Enliven Therapeutics, Inc. is a pharmaceutical company focused on developing innovative therapies for various health conditions. As part of the Health Care sector, its work is crucial in addressing unmet medical needs and improving patient outcomes.

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

75%

Avg EPS Surprise

+15.56%

Avg Stock Reaction

-0.48%

Last Quarter Recap

In Q1 2026, Enliven reported an EPS of -$0.38, which was better than the expected -$0.44, resulting in a positive surprise of 13.64%. However, the stock price fell by 2.21% the following day.

Management Promises & Guidance

Expectations

Wall Street Expectations

Overall, investors are cautious as there are no analyst estimates available, and the company has shown mixed performance in previous quarters.

Bull Case

If Enliven can continue to beat EPS estimates, it may signal improving operational efficiency and investor confidence, potentially driving the stock higher.

Bear Case

Conversely, if the company fails to meet expectations or provides weak guidance, it could raise concerns about its long-term viability, leading to further declines.

Expectations

Two Questions That Matter

The print will turn on these two things.

What will the EPS be this quarter, and how does it compare to past estimates?

Given the company's recent performance, the EPS figure will be closely scrutinized to determine if the trend of beating estimates continues.

What insights can management provide regarding revenue growth and future guidance?

Investors will be looking for clarity on revenue trends, as this will impact perceptions of the company's growth potential.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may be underestimating the potential for Enliven to surprise positively on EPS due to recent operational improvements not yet reflected in analyst estimates.

Supporting Evidence

The company has a 75% EPS beat rate, indicating a strong likelihood of exceeding expectations.

Options are pricing a 39% move, suggesting that the market anticipates significant volatility, which could favor a positive surprise.

Key Risk

If the EPS comes in significantly better than expected, it could shift market sentiment and validate the company's growth narrative.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

The market is weighing the potential for continued improvement against the backdrop of previous mixed results.

Bull Confirmed If

A positive EPS surprise of at least 10% would confirm the bull case and suggest improving financial health.

Bear Confirmed If

An EPS miss of more than 10% would confirm the bear case and raise concerns about the company's operational challenges.

Pre-Earnings Positioning

Options Market

Implied Move

±39.04%

Historical Avg

±3.0%

Pricing rich

The options market is pricing in a significant potential move, indicating heightened uncertainty or anticipation around the earnings report.

Options are pricing ±39.0% while ELVN has averaged ±3.0% over the last 8 prints — setup is pricing rich.

Detail

ATM IV

0.9%

30d HV

45.5%

Calls (3K)P/C Ratio: 0.99Puts (39K)

Edge

Historical Setup Match

Cross-company pattern from 30 similar setups.

Prior-quarter beat + options rich in Health Care

n=30

Fade rate: 13 of 29 (45%)

This setup has occurred 30 times across Health Care in the last 2 years. 13 of 29 faded and 16 held — no strong directional bias after the initial reaction. The average absolute 1-day move is 5.5%, with a raw directional average of +2.9% (modestly positive historical bias).

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If Enliven beats expectations, history suggests the stock could see a modest increase of around 3.36% on the following day, confirming a positive trend.

In-Line / Cautious

If results are in line with expectations, the stock may experience a muted reaction as investors await further commentary from management.

Miss

If the company misses expectations, history suggests a decline of approximately 1.62%, raising concerns about its future prospects.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Any updates on new drug developments or pipeline progress.
2Management's outlook on revenue growth for the upcoming quarters.
3Insights on cost management and operational efficiency improvements.
4Details on market conditions and competitive landscape affecting performance.
5Any changes in strategic direction or partnerships that could impact future growth.

See the full picture

AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.

No charge today · Auto-bills $8/mo after 7 days · Cancel anytime

More Earnings This Week

5 Reports

Aug10

BWBMO

Babcock & Wilcox Enterprises, Inc.

PreviewView

Aug10

ROIVBMO

Company Snapshot

Enliven Therapeutics, Inc. is a pharmaceutical company focused on developing innovative therapies for various health conditions....

Key Metrics to Watch

Earnings Per Share (EPS)

EPS is a key indicator of profitability and will help investors gauge the company's financial health this quarter.

N/A

Revenue Growth

Understanding revenue trends is essential for assessing the company's market performance and potential for future growth.

N/A

Wall Street expectations, options signals, track record, and call prep available with Pro.

ELVN Q2-2026 Earnings Preview

Context

Company Snapshot

Earnings Scorecard·Last 8Q

EPS Beat Streak

EPS Beat Rate

75%

Avg EPS Surprise

+15.56%

Avg Stock Reaction

-0.48%

Last Quarter Recap

In Q1 2026, Enliven reported an EPS of -$0.38, which was better than the expected -$0.44, resulting in a positive surprise of 13.64%. However, the stock price fell by 2.21% the following day.

Management Promises & Guidance

Expectations

Wall Street Expectations

Overall, investors are cautious as there are no analyst estimates available, and the company has shown mixed performance in previous quarters.

Bull Case

If Enliven can continue to beat EPS estimates, it may signal improving operational efficiency and investor confidence, potentially driving the stock higher.

Bear Case

Conversely, if the company fails to meet expectations or provides weak guidance, it could raise concerns about its long-term viability, leading to further declines.

Expectations

Two Questions That Matter

The print will turn on these two things.

What will the EPS be this quarter, and how does it compare to past estimates?

Given the company's recent performance, the EPS figure will be closely scrutinized to determine if the trend of beating estimates continues.

What insights can management provide regarding revenue growth and future guidance?

Investors will be looking for clarity on revenue trends, as this will impact perceptions of the company's growth potential.

Edge

What the Street Is Missing

Why consensus could be wrong

The Street may be underestimating the potential for Enliven to surprise positively on EPS due to recent operational improvements not yet reflected in analyst estimates.

Supporting Evidence

The company has a 75% EPS beat rate, indicating a strong likelihood of exceeding expectations.

Options are pricing a 39% move, suggesting that the market anticipates significant volatility, which could favor a positive surprise.

Key Risk

If the EPS comes in significantly better than expected, it could shift market sentiment and validate the company's growth narrative.

Edge

Thesis-Break Levels

Pre-commit to what would confirm each case.

The market is weighing the potential for continued improvement against the backdrop of previous mixed results.

Bull Confirmed If

A positive EPS surprise of at least 10% would confirm the bull case and suggest improving financial health.

Bear Confirmed If

An EPS miss of more than 10% would confirm the bear case and raise concerns about the company's operational challenges.

Pre-Earnings Positioning

Options Market

Implied Move

±39.04%

Historical Avg

±3.0%

Pricing rich

The options market is pricing in a significant potential move, indicating heightened uncertainty or anticipation around the earnings report.

Options are pricing ±39.0% while ELVN has averaged ±3.0% over the last 8 prints — setup is pricing rich.

Detail

ATM IV

0.9%

30d HV

45.5%

Calls (3K)P/C Ratio: 0.99Puts (39K)

Edge

Historical Setup Match

Cross-company pattern from 30 similar setups.

Prior-quarter beat + options rich in Health Care

n=30

Fade rate: 13 of 29 (45%)

Preparation

Post-Print Playbook

Likely market behavior by outcome — not investment advice.

Beat & Raise

If Enliven beats expectations, history suggests the stock could see a modest increase of around 3.36% on the following day, confirming a positive trend.

In-Line / Cautious

If results are in line with expectations, the stock may experience a muted reaction as investors await further commentary from management.

Miss

If the company misses expectations, history suggests a decline of approximately 1.62%, raising concerns about its future prospects.

Earnings Track Record

Preparation

What to Listen For

Call Prep

1Any updates on new drug developments or pipeline progress.
2Management's outlook on revenue growth for the upcoming quarters.
3Insights on cost management and operational efficiency improvements.
4Details on market conditions and competitive landscape affecting performance.
5Any changes in strategic direction or partnerships that could impact future growth.